2015 James W. Freston Single Topic Conference: A Renaissance in the Understanding and Management of Irritable Bowel Syndrome

Lin Chang; Margaret M. Heitkemper; John W. Wiley; Michael Camilleri

doi:10.1016/j.jcmgh.2016.05.014

2015 James W. Freston Single Topic Conference: A Renaissance in the Understanding and Management of Irritable Bowel Syndrome

Lin Chang, Margaret M. Heitkemper, John W. Wiley, Michael Camilleri

Gastroenterology and Hepatology

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Original language	English (US)
Pages (from-to)	394-399.e2
Journal	CMGH
Volume	2
Issue number	4
DOIs	https://doi.org/10.1016/j.jcmgh.2016.05.014
State	Published - Jul 1 2016

ASJC Scopus subject areas

Hepatology
Gastroenterology

Access to Document

10.1016/j.jcmgh.2016.05.014

Cite this

@article{ac02137e020541309e1161e2864a564c,

title = "2015 James W. Freston Single Topic Conference: A Renaissance in the Understanding and Management of Irritable Bowel Syndrome",

author = "Lin Chang and Heitkemper, {Margaret M.} and Wiley, {John W.} and Michael Camilleri",

note = "Funding Information: Conflicts of interest These authors disclose the following conflicts: Lin Chang has served on scientific advisory boards for Takeda, AstraZeneca, Allergan, QOL Medical, Ardelyx, Synergy, Commonwealth Laboratories, and Ironwood, Synthetics Biologics, and IM Health Science. John Wiley is recipient of a research grant from Takeda Pharmaceuticals. Michael Camilleri has received research support in the field of IBS in the past 3 years from Tsumura, Salix, and EnteraHealth, and he has done consulting in the field of IBS in the past 3 years with GlaxoSmithKline with remuneration to his employer, Mayo Clinic. The remaining author discloses no conflicts. Funding Information: Funding The Freston conference is supported by a Takeda endowment to the American Gastroenterological Association. Funding Information: A heritable component of IBS is supported by family and twin studies and a Swedish proband study. To date, there have been limited findings in candidate gene studies; one of the fundamental flaws has been the need for ≥2000 patients to achieve the P values of 10 -7 typically required in genetic association studies. One exception is TNFSF15 gene, which is associated with risk of IBS in several European and US cohorts. 2 The first genome-wide association study of IBS in 5466 individuals from a Swedish population-based (twin) cohort, identified 1 locus at 7p22.1, which includes the genes KDELR2 (KDEL endoplasmic reticulum protein retention receptor 2) and GRID2IP (glutamate receptor, ionotropic, delta 2 [Grid2] interacting protein), which showed consistent IBS risk effects. 3 This finding was replicated in 6 case-control cohorts from Europe and the United States. Currently, a collaborative project is examining genetics of IBS in >30,000 European population-based cohorts, and in well-characterized IBS patients and controls from Europe and the United States. ",

year = "2016",

month = jul,

day = "1",

doi = "10.1016/j.jcmgh.2016.05.014",

language = "English (US)",

volume = "2",

pages = "394--399.e2",

journal = "Cellular and Molecular Gastroenterology and Hepatology",

issn = "2352-345X",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - 2015 James W. Freston Single Topic Conference

T2 - A Renaissance in the Understanding and Management of Irritable Bowel Syndrome

AU - Chang, Lin

AU - Heitkemper, Margaret M.

AU - Wiley, John W.

AU - Camilleri, Michael

N1 - Funding Information: Conflicts of interest These authors disclose the following conflicts: Lin Chang has served on scientific advisory boards for Takeda, AstraZeneca, Allergan, QOL Medical, Ardelyx, Synergy, Commonwealth Laboratories, and Ironwood, Synthetics Biologics, and IM Health Science. John Wiley is recipient of a research grant from Takeda Pharmaceuticals. Michael Camilleri has received research support in the field of IBS in the past 3 years from Tsumura, Salix, and EnteraHealth, and he has done consulting in the field of IBS in the past 3 years with GlaxoSmithKline with remuneration to his employer, Mayo Clinic. The remaining author discloses no conflicts. Funding Information: Funding The Freston conference is supported by a Takeda endowment to the American Gastroenterological Association. Funding Information: A heritable component of IBS is supported by family and twin studies and a Swedish proband study. To date, there have been limited findings in candidate gene studies; one of the fundamental flaws has been the need for ≥2000 patients to achieve the P values of 10 -7 typically required in genetic association studies. One exception is TNFSF15 gene, which is associated with risk of IBS in several European and US cohorts. 2 The first genome-wide association study of IBS in 5466 individuals from a Swedish population-based (twin) cohort, identified 1 locus at 7p22.1, which includes the genes KDELR2 (KDEL endoplasmic reticulum protein retention receptor 2) and GRID2IP (glutamate receptor, ionotropic, delta 2 [Grid2] interacting protein), which showed consistent IBS risk effects. 3 This finding was replicated in 6 case-control cohorts from Europe and the United States. Currently, a collaborative project is examining genetics of IBS in >30,000 European population-based cohorts, and in well-characterized IBS patients and controls from Europe and the United States.

PY - 2016/7/1

Y1 - 2016/7/1

UR - http://www.scopus.com/inward/record.url?scp=84975298425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975298425&partnerID=8YFLogxK

U2 - 10.1016/j.jcmgh.2016.05.014

DO - 10.1016/j.jcmgh.2016.05.014

M3 - Article

AN - SCOPUS:84975298425

VL - 2

SP - 394-399.e2

JO - Cellular and Molecular Gastroenterology and Hepatology

JF - Cellular and Molecular Gastroenterology and Hepatology

SN - 2352-345X

IS - 4

ER -

2015 James W. Freston Single Topic Conference: A Renaissance in the Understanding and Management of Irritable Bowel Syndrome

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this